Pharmacist-managed titration of urate-lowering therapy to streamline gout management

被引:8
作者
Huang, Irvin J. [1 ]
Liew, Jean W. [2 ]
Morcos, Meredith B. [3 ]
Zuo, Silu [4 ]
Crawfords, Carol [5 ]
Bays, Alison M. [2 ]
机构
[1] Univ Washington, Dept Med, Boise, ID USA
[2] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA
[3] Virginia Mason Med Ctr, Rheumatol, Seattle, WA 98101 USA
[4] Univ Washington, Pharm, Seattle, WA 98195 USA
[5] Harborview Med Ctr, Pharm, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
Crystal arthropathies; Hyperuricemia; Gout; Patient compliance; US GENERAL-POPULATION; CARE; ADHERENCE; HYPERURICEMIA; PREVALENCE; GUIDELINES; HEALTH; TARGET; TREAT;
D O I
10.1007/s00296-019-04333-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.
引用
收藏
页码:1637 / 1641
页数:5
相关论文
共 50 条
  • [41] Adherence with urate-lowering therapies for the treatment of gout
    Leslie R Harrold
    Susan E Andrade
    Becky A Briesacher
    Marsha A Raebel
    Hassan Fouayzi
    Robert A Yood
    Ira S Ockene
    Arthritis Research & Therapy, 11
  • [42] Adherence with urate-lowering therapies for the treatment of gout
    Harrold, Leslie R.
    Andrade, Susan E.
    Briesacher, Becky A.
    Raebel, Marsha A.
    Fouayzi, Hassan
    Yood, Robert A.
    Ockene, Ira S.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
  • [43] Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
    Matthew J. Coleshill
    Eindra Aung
    Jane E. Carland
    Kate Faasse
    Sophie Stocker
    Richard O. Day
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 138 - 141
  • [44] Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China
    Bai, Xue-Shan
    Wang, Ming
    Zhao, Xiao-Dong
    Cui, Ling-Ling
    He, Yu-Wei
    Wang, Can
    Li, Xin-De
    Qu, Xiao-Jie
    Sun, Ming-Shu
    Li, Chang-Gui
    TECHNOLOGY AND HEALTH CARE, 2021, 29 (01) : 121 - 131
  • [45] Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database
    Liu, Ching-Han
    Huang, Shih-Chung
    Yin, Chun-Hao
    Huang, Wei-Chun
    Chen, Jin-Shuen
    Chen, Yao-Shen
    Gan, Su-Ting
    Tzou, Shiow-Jyu
    Hsu, Ching-Tsai
    Wu, Hao-Ming
    Wang, Wen-Hwa
    BIOMEDICINES, 2023, 11 (01)
  • [46] What is the Best Choice for Urate-lowering Therapy for Korean?
    Cheon, Yun-Hong
    Song, Jung Soo
    JOURNAL OF RHEUMATIC DISEASES, 2020, 27 (02): : 78 - 87
  • [47] Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial
    Mikuls, Ted R.
    Cheetham, T. Craig
    Levy, Gerald D.
    Rashid, Nazia
    Kerimian, Artak
    Low, Kimberly J.
    Coburn, Brian W.
    Redden, David T.
    Saag, Kenneth G.
    Foster, P. Jeffrey
    Chen, Lang
    Curtis, Jeffrey R.
    AMERICAN JOURNAL OF MEDICINE, 2019, 132 (03) : 354 - 361
  • [48] Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review
    Virginie Beslon
    Perrine Moreau
    Annabel Maruani
    Hubert Maisonneuve
    Bruno Giraudeau
    Jean-Pascal Fournier
    Journal of General Internal Medicine, 2018, 33 : 358 - 366
  • [49] Urate-lowering therapy exerts protective effects against hypertension development in patients with gout
    Lin, Kuan-Hung
    Yen, Fu-Shun
    Li, Hsin-Lun
    Wei, James Cheng-Chung
    Hsu, Chih-Cheng
    Yang, Chen-Chang
    Hwu, Chii-Min
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (04) : 351 - 359
  • [50] Factors associated with initiation and persistence of urate-lowering therapy
    Dehlin, Mats
    Ekstrom, Emin Hoxha
    Petzold, Max
    Stromberg, Ulf
    Telg, Gunilla
    Jacobsson, Lennart T. H.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19